About Sharon Bio-Medicine Ltd.


Sharon Bio-Medicine Ltd. is an Indian pharmaceutical company based in Navi Mumbai, Maharashtra. Established in 1989 as a manufacturer of Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (APIs), the company started manufacturing Finished Dosages in 2007.


The company also offers services such as chemical process development and scale-up, formulation development, analytical method development, DMF and dossier preparation, stability monitoring through a product’s shelf life.


Company Highlights

  • Exports to all markets including regulated markets such as USA, Europe and Australia
  • 2 API manufacturing facilities at Taloja, Navi Mumbai, Maharashtra, India.
  • Manufactures finished dosages mainly for pharmaceutical companies in areas such as oncology, dermatology, antibiotics, liquid orals, capsules and suppositories.
  • The company started a separate division for pre-clinical toxicology testing, called SA-FORD (Sanctuary for Research and Development in 2008. SA-FORD is an OECD GLP certified Contract Research Organization (CRO) specializing in chemistry, mutagenicity & toxicological studies on rodents. The division works strictly according to international regulatory guidelines, such as OECD, EPA, ICH, EC, EMEA, CIPAC, etc.


Sharon Bio-Medicine Ltd. is listed on both Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).


Sharon Bio-Medicine Limited at-a-glance

  • Total Revenue (9 months; 31 March, 2016) ~USD 38.5 million^

?255.4 crores

  • Employees (31 March, 2016) 525
  • Manufacturing Facilities 3
  • R&D Facility 2

Approvals Certifications

  • WHO
  • KFDA
  • EDQM
  • GMP
  • INVIMA (Colombia)
  • NDA Uganda
  • SDA Yemen
  • MSS Namibia
  • Health Canada
  • TGA Australia
  • US FDA
  • ISO 10993
  • ICH certified




Company Annual Report

^As per Reserve Bank of India’s Reference Rate for the US Dollar ?66.3329 on March 31, 2016.



Sharon Bio-Medicine Ltd. was incorporated in 1989. The company went public in 2000 with an offering of 25% of its shares.



  • 1989: Sharon Bio-Medicine Limited is established
  • 1995:
    • Starts manufacture of Pharmaceutical Intermediates
    • API manufacturing unit 1 in Navi Mumbai, Maharashtra, India is commissioned
  • 1997: Commences the manufacture of Active Pharmaceutical Ingredients (APIs)
  • 2000:
  • Goes public
  • Sets up an R&D Centre for the development of Active Pharmaceutical Ingredients and Intermediates
  • 2001: Commences exports to non-regulated markets
  • 2007: State-of-art manufacturing facility for Formulations / Finished Dosages is commissioned at Dehradun, Uttarakhand, India
  • 2009:
    • Sets up a division called SA-FORD (Sanctuary for Research and Development) for conducting toxicology studies
    • API manufacturing unit 2 in Navi Mumbai, Maharashtra, India is commissioned
  • 2010 - 2011:
    • Manufacturing facility for finished dosage gets approval from Health Canada, TGA Australia, UK MHRA
    • API manufacturing unit 2 is granted first CEP product Trimetazidine Dihydrochloride
    • 3 DMFs filed with USFDA.
  • 2014: API manufacturing unit 2 gets KFDA and EDQM GMP Certification



  • Managing Director Mrs. Savita Satish Gowda
  • Executive Director Mr. Lalit Misra
  • Non-Executive Director Dr. Nivedita Patil
  • Non-Executive Director Mr. Harish Palecanda





Sharon Bio-Medicine Ltd.

C-312, BSEL Tech Park, Sector 30 (A)

Opposite Vashi Railway Station, Vashi

Navi Mumbai – 400703

Maharashtra, India


Website: www.sharonbio.com

Tel: +91 22-67944000

Fax: +91-22-67944001


API domestic@sharonbio.com, export@sharonbio.com

Formulation formulation@sharonbio.com

Purchase purchase@sharonbio.com





* Indicates mandatory field.
Please wait while comments are being sent...